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H
epatitis D virus (HDV) was discovered by 
Rizzetto  et  al.  (1)  and  after  its  discovery, 
the  role  of  HDV  infection  in  the  exacerbation  of 
hepatitis  B  virus  (HBV)  infection  was  revealed. 
Hepatitis D virus infection occurs worldwide, but 
data about its incidence and prevalence are different 
in different parts of the world (2). The epidemiology 
of HDV infection is similar to that of HBV, with 
notable exceptions. It is estimated that approximately 
5% of hepatitis B surface antigen (HBsAg) carriers 
are infected with HDV infection worldwide (3). The 
infection  had  been  endemic  in  the  Mediterranean 
basin,  the  Middle  East,  and  parts  of  Africa  (4-6). 
However, the rate of HDV infection has decreased in 
many countries of the world, due to the introduction 
of HBV vaccination, subsequently decreasing HBV 
infection and thus the pool of HBsAg carriers who 
may also be infected with HDV(7). Socioeconomic 
improvements, and measures introduced to control 
the human immunodeficiency virus (HIV), are also 
responsible for this decrease. Nonetheless, HDV still 
continues to represent a public health problem in 
some parts of the world (8-12).
Thirty years after the discovery of HDV (13), there 
are still some clinical findings that should be clarified 
and addressed. I would like to mention some of these 
issues and ask scientists to think more about them, 
and send us their comments, as letters to the editor.
First 
An  observation:  A  36-year-old  HBsAg  positive 
man was referred to our clinic after the detection of 
HBV infection in his family one year earlier. He was 
totally asymptomatic and the first evaluation showed 
abnormal  alanine  aminotransferase  (ALT;  60  IU/
ml), a high viral load for HBV infection (125,000 
IU/ml by Amplicor version 2 test), and the antibody 
to  HDV  (anti-HDV  Ab)  and  HDV  RNA  were 
positive. I recommended liver biopsy and treatment. 
Unfortunately, he declined to continue with us. After 
two years, he came back, and our evaluation showed 
that he had become HDV RNA-negative without any 
intervention.
A question: Did seroconversion occur without any 
therapy, in a non-acute case of hepatitis D, or had it 
been an HDV RNA-negative case in the first place? 
Was it a diagnostic mistake?
Comments: First of all, I would like to discuss 
the sensitivity and specificity of the tests. The anti-
HDV  Ab  is  detected  by  using  an  enzyme-linked 
immunosorbent  assay  (ELISA)  kit  (Radim  SpA, 
Pomezia,  Italy)  according  to  the  manufacturer’s 
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protocol  with  >  98%  sensitivity  and  specificity; 
and  for  molecular  study  (14),  RNA  was  extracted 
from the patient’s serum by using the QIAmp Viral 
RNA  Mini  Kit  according  to  the  manufacturer’s 
instructions  (Qiagen  GmbH,  Germany);  and  for 
reverse transcription, 10μl of extracted RNA was used 
in  a  reaction  tube  containing  reverse  transcription 
buffer (50 mM Tris-HCl[PH8.3], 50 mM KCl, 4mM 
MgCl2), 100 pmol random primers,12U of RNase 
Inhibitor ,60 U of Molony-Murine Leukemia virus 
reverse  transcriptase,  1  mM  deoxyribonucleoside 
triphosphate (dNTP) and 4μl of diethyl pyrocarbonate 
treated water (DEPC). The reaction was incubated at 
42Ċ for 30min on an Eppendorf Personal Thermal 
Cycler (Eppendorf, Germany). cDNA was amplified 
using sequence specific primers for HDV, according to 
the published method (15). For cDNA amplification, 
in the first round of the polymerase chain reaction 
(PCR),  5μl  of  cDNA  was  added  to  a  PCR  tube 
containing 2.5μl of 10x PCR buffer, 1.5 mM MgCl2, 
0.2mM  dNTP,  5U Taq  DNA  polymerase  (Roche, 
Germany)  and100  pmol  of  each  external  primer 
5413,  8276.  For  the  nested  PCR  reaction,  2μl  of 
the PCR product from the first amplification were 
added to the second PCR tube containing internal 
primers 5414, 5415 and the same reagents as in the 
first round of the PCR. The amplification products 
were separated on a 2% agarose gel and an expected 
405bp PCR product, visualized by ethidium bromide 
staining, confirmed the presence of HDV RNA in 
the patient’s serum. Unfortunately, the sensitivity and 
specificity of molecular tests is not reliable in Iran. 
Secondly, there are some data regarding mismatching 
between  anti-HDV  Ab  positivity  and  HDV  RNA 
findings, in the literature. I think some patients with 
a history of confronting HDV infection can eliminate 
the virus, and be mono-infected with HBV infection. 
The natural course of HDV is not totally known yet 
(16), but recovery from acute hepatitis D infection is 
possible (17). I think the patient’s age when acquiring 
HDV infection can affect its course and outcomes. 
Most Iranian patients co-infected with HDV/HBV 
acquire the infection in childhood (2, 8, 18). On the other 
hand, there are at least three distinct HDV genotypes, 
and these genotypes can affect the remission rate and 
the adverse outcomes of the infection. I would like to 
mention that the predominant genotype in the Iranian 
population is type I (14). On the other hand, the HBV 
genotypes exert a significant influence on remission 
rate and adverse outcomes too. Genotype C has a 
lower remission rate and more adverse outcomes than 
genotype B (19). The main HBV genotype identified 
in Iran has been genotype D, and unfortunately we 
have not been able to find any data regarding the 
influence of HBV genotype D on the course of HDV 
infection in the literature.
What do others say?
Second
An  observation:  A  25-year-old  man  had  been 
HBsAg positive for 2 years, with normal ALT (42 IU/
ml) and aspartate aminotransferase (AST; 35 IU/ml) 
levels, negative hepatitis B e antigen (HBeAg), and 
positive HDV Ab and HDV RNA in the serum. A 
liver biopsy was performed and revealed grade 2 and 
stage zero, according to Knodel scoring.
A question: Can we define it as a case of a carrier 
state of HDV infection?
Comments: We are not really sure what defines 
“carrier state” in HDV infection. First of all, I would 
like to pose a question about the normality of ALT 
in this case. I think the result of 40 or 45 IU/ml may 
be high and should really not be considered within 
the normal range  (20). Second, we need to do the 
measurement of ALT more than once, and at different 
times, for better interpretation of the results. Third, 
it is well known that liver biopsy is associated with a 
significant rate of false negative results in the diagnosis 
of  chronic  hepatitis  D  infection  (21).  In  addition, 
the accuracy of the histological assessment of necro-
inflammation and fibrosis are dependent on the size 
of the specimen.
What do others say?
Third
An  observation:  A  25-year-old  HBsAg  positive 
man was diagnosed after family screening for HBV 
infection. His mother was the first in the family to be 
diagnosed (as cirrhotic) the year before. In addition, 
two of his brothers and one of his sisters were also 
affected. The results of laboratory tests in this case 
were: elevated ALT (98 IU/ml), negative HBeAg and 
anti HDV Ab. The HBV viral load was determined 
to be 125 IU/ml by the Amplicor, version 2, test. 
Liver biopsy revealed severe damage to hepatic cells 
(grade 8 and stage 4, according to Knodel scoring). 
Interestingly, HDV RNA was shown to be positive.
Questions: There are many questions here. First, is 
it enough to require evidence of the anti-HDV Ab in 
the evaluation of chronic hepatitis B-infected patients? 
Also, can we rule out HDV infection on this basis? 
Does using HDV RNA in addition to the anti HDV 
Ab test as the screening test make a difference, in cases 
that are suspected to have been affected with HBV 
and HDV infection during their childhood, directly 
or vertically?Hepatitis Monthly, Spring 2010; 10(2): 77-79
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Comments: I would like to coin a new term with 
reference to HDV infection “Occult HDV”, and ask 
you to produce more evidence in the field of HDV 
diagnosis, especially regarding primers and serological 
evaluation and an improvement in the sensitivity and 
specificity of tests.
What do others say?
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